D54 Inhibitors
Chemical inhibitors of D54 include a range of compounds that target various kinases and signaling pathways involved in the regulation of this protein's activity. Staurosporine can inhibit D54 by targeting protein kinases that are crucial for its activation within signaling pathways. By preventing the phosphorylation of proteins that are either upstream or downstream of D54, Staurosporine disrupts the normal signaling cascade that D54 is part of, leading to its functional inhibition. Similarly, Bisindolylmaleimide I, a selective inhibitor of protein kinase C (PKC), can reduce the phosphorylation events necessary for D54's function, thereby inhibiting it. LY294002 and Wortmannin, both phosphoinositide 3-kinases (PI3K) inhibitors, can lead to D54 inhibition by disrupting the PI3K/Akt pathway, which is often implicated in the regulation of proteins like D54.
U0126 and PD98059, which inhibit mitogen-activated protein kinase kinase (MEK), can prevent the activation of the extracellular signal-regulated kinase (ERK) within the MAPK pathway. Since D54's activity can be modulated by the MAPK pathway, inhibiting MEK and consequently ERK can lead to the functional inhibition of D54. SB203580, by inhibiting p38 MAPK, and SP600125, by inhibiting c-Jun N-terminal kinase (JNK), can also functionally inhibit D54 by blocking the regulatory signals within their respective pathways that would modulate D54 activity. Rapamycin inhibits the mammalian target of rapamycin (mTOR), and since D54 may be associated with pathways controlled by mTOR, its inhibition can reduce D54's activity by disrupting the signaling required for its function. PP2, as an inhibitor of Src family tyrosine kinases, can decrease D54 activity by preventing its regulation through tyrosine phosphorylation. Gefitinib and Erlotinib, both inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase, can inhibit D54 by blocking the downstream signaling events in pathways regulated by EGFR that would otherwise modulate D54 activity. The inhibition of EGFR by these compounds disrupts the signaling pathways that control D54 activity, leading to its functional inhibition.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. D54 protein is involved in signaling pathways that rely on kinase activity. By inhibiting the kinases that would normally phosphorylate proteins downstream or upstream of D54, Staurosporine can prevent D54 from fulfilling its role in the signal transduction pathway, leading to its functional inhibition. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
This compound selectively inhibits protein kinase C (PKC), which is involved in numerous signaling pathways, including those that may involve D54. Inhibiting PKC can reduce phosphorylation events that are necessary for D54 to function within its pathway, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K), which participate in the Akt signaling pathway. D54 protein may interact with components of the PI3K/Akt pathway, and inhibiting this pathway can lead to a decrease in the functional activity of D54, as it may rely on PI3K/Akt for its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. If D54's function is modulated by the p38 MAPK pathway, then inhibiting this kinase can lead to the functional inhibition of D54 by blocking the regulatory signals that would normally modulate its activity within this signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), a key kinase in regulating cell growth and proliferation. If D54 is associated with pathways controlled by mTOR, then inhibition of mTOR can lead to a reduction in D54 activity by disrupting the signaling required for its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 can prevent the activation of ERK and thus inhibit the functional activity of D54 if D54 activity is associated with the MAPK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). If the function of D54 is regulated in part by the JNK signaling pathway, inhibiting JNK can lead to the functional inhibition of D54 by blocking the signals that modulate its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, and like LY294002, it can lead to functional inhibition of D54 by inhibiting the PI3K/Akt pathway which may be necessary for D54's activity or the activity of proteins that regulate D54. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. If D54 is regulated by pathways involving Src kinases, the inhibition of these kinases by PP2 can lead to a decrease in D54 activity by preventing its proper regulation through tyrosine phosphorylation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. If D54 is involved in signaling pathways that are regulated by EGFR, then inhibition of EGFR by Gefitinib can lead to functional inhibition of D54 by blocking the downstream signaling events that would otherwise modulate D54 activity. | ||||||